Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines PipelineBenzinga • 09/30/24
Wall Street Analysts Believe Prime Medicine, Inc. (PRME) Could Rally 120.95%: Here's is How to TradeZacks Investment Research • 05/30/24
If You Can Only Buy One Biotech Stock in May, It Better Be One of These 3 NamesInvestorPlace • 05/29/24
Here Are the 2 Growth Stocks Google's Parent Company Just Added to Its $7 Billion PortfolioThe Motley Fool • 05/25/24
Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for May 2024InvestorPlace • 05/17/24
Does Prime Medicine, Inc. (PRME) Have the Potential to Rally 133.64% as Wall Street Analysts Expect?Zacks Investment Research • 05/14/24
Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQGlobeNewsWire • 05/13/24
Prime Medicine Reports First Quarter 2024 Financial Results and Provides Business UpdatesGlobeNewsWire • 05/10/24
Prime Medicine Presents Preclinical Data Demonstrating Ability of PM359 to Efficiently, Reproducibly and Durably Correct Causative Mutation of Chronic Granulomatous Disease (CGD)GlobeNewsWire • 05/08/24
Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)GlobeNewsWire • 04/29/24
Prime Medicine to Present Preclinical Data Demonstrating Broad Potential of Prime Editing Technology at Upcoming Scientific MeetingsGlobeNewsWire • 04/23/24
Prime Medicine Reports Full Year 2023 Financial Results and Provides Business UpdatesGlobeNewsWire • 03/01/24